Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
VANCOUVER, British Columbia, May 18, 2023 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage…
News
BioSyent Schedules Q1 2023 Earnings Release for May 26, 2023
MISSISSAUGA, Ontario, May 18, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture:…
Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
18 May 2023 Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of…
inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology
Gastro Health, a leading gastroenterology group, plans to utilize this simplified blood collection method when…
Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates
uBriGene (Boston) Biosciences to acquire Mustang Bio’s Worcester manufacturing facility for total consideration of up…
Outpace Bio to Present New Data on OutSmart™ IL-2/15, a CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity, at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Seattle, WA, May 18, 2023 (GLOBE NEWSWIRE) — Outpace Bio, a company using protein design…
VYNE Therapeutics to Attend BIO International Convention
BRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or…
Just in Time for Summer, SweetWater Brewing Introduces Colorado Orange Citrus Ale, a Refreshing New Beer Crafted Exclusively for the High Country
SweetWater Brewing Introduces New Limited Colorado Orange SweetWater ORANGE is brewed with Centennial hops and…
InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
TEL AVIV, Israel and MIAMI, May 18, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR),…
Motus GI Announces $3.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FORT LAUDERDALE, Fla., May 18, 2023 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS)…
PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
Company plans to initiate VERSATILE-003 Phase 3 clinical trial in late 2023 FLORHAM PARK, N.J.,…
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
Rucosopasem in clinical development to augment the anti-cancer efficacy of stereotactic body radiation therapy MALVERN,…
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed…
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc)…
Science 37 Wins 2023 MedTech Breakthrough Award for “Best Overall Clinical Trial Platform”
Science 37’s unified platform that powers the Metasite receives award for outstanding digital health and technology…
Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease
– First Human Evidence that CT1812 Selectively Engages Aβ Oligomers PURCHASE, N.Y., May 18, 2023…
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa Plan to file supplemental New…
Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications
Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe…
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
In the Phase 1 trial, KT-474 showed evidence of robust IRAK4 degradation in blood and…
Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference
CHATHAM, N.J., May 18, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a…